Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer (UCDCC#215)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00814788
Recruitment Status : Completed
First Posted : December 25, 2008
Results First Posted : June 1, 2017
Last Update Posted : January 10, 2018
Information provided by (Responsible Party):
University of California, Davis

December 24, 2008
December 25, 2008
March 6, 2017
June 1, 2017
January 10, 2018
December 2008
December 2015   (Final data collection date for primary outcome measure)
PSA Response Rate [ Time Frame: Up to 2 years ]
The PSA response rate was defined as a 30% reduction in the PSA level from baseline. PSA Working Group consensus criteria combined with radiographic studies were used to determine the proportion of patients with PSA decline.
PSA response rate (i.e., a 30% reduction in the PSA level from baseline)
Complete list of historical versions of study NCT00814788 on Archive Site
  • Progression-free Survival [ Time Frame: Up to 2 years ]
    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
  • Overall Survival [ Time Frame: Up to 3 years ]
    Overall survival was estimated using the Kaplan-Meier method.
  • Progression-free Survival
  • Time to treatment failure
  • Overall Survival
  • Toxicity rates as assessed by NCI CTCAE v3.0
Not Provided
Not Provided
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
Phase II Trial of Bicalutamide and RAD001 in Patients With Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying bicalutamide and everolimus to see how well they work compared with bicalutamide in treating patients with recurrent or metastatic prostate cancer.


  • To compare the PSA response rate in patients with hormone-independent recurrent or metastatic adenocarcinoma of the prostate treated with bicalutamide and everolimus after first-line androgen deprivation therapy.
  • To evaluate the time to treatment failure and overall survival of these patients.
  • To assess the toxicity of bicalutamide and everolimus in these patients.

OUTLINE: Patients are stratified according to disease status (metastatic disease vs biochemical recurrence without measurable disease).

Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 28-42 days and then every 3 months thereafter.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Prostate Cancer
  • Drug: Bicalutamide
    50 mg oral tablet daily
    Other Name: Casodex
  • Drug: Everolimus
    10 mg oral capsule daily
    Other Names:
    • Afinitor
    • RAD001
Experimental: Bicalutamide + Everolimus
Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
  • Drug: Bicalutamide
  • Drug: Everolimus
Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 Jun 15;122(12):1897-904. doi: 10.1002/cncr.29927. Epub 2016 Mar 28.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2016
December 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria

  1. Participants must be adult males >18 years.
  2. Patients must have histologically or cytologically confirmed CaP with a Gleason score available or interpretable.
  3. Patients must have CaP deemed to be androgen independent.
  4. Measurable disease is not required.
  5. Patients must have been surgically or medically castrated. If the method of castration was LHRH agonists (leuprolide or goserelin) or antagonists (degarelix), then the patient must be willing to continue the use of LHRH agonists or antagonists. Serum testosterone must be at castrate levels (< 50 ng/dL) within 3 months prior to registration.
  6. Participant has not been on any previous therapy with androgen receptor antagonists or mTOR inhibitors. Note: patients who have taken an androgen receptor antagonist for a brief period (no more than 2 months) at the start of LHRH agonist therapy to prevent flare will be considered eligible.
  7. Men enrolled in this trial must agree to use adequate contraception prior to study entry and for the duration of study participation.
  8. Patients must have normal organ and marrow function.
  9. Ability to understand and the willingness to sign a written informed consent document
  10. ECOG performance status 0-2.
  11. Patients having any respiratory symptoms such as cough and shortness of breath have undergone pulmonary function testing revealing no worse than mild impairment.

Exclusion Criteria

  1. No documented histological confirmation of CaP.
  2. Patient has received other hormonal therapy besides first-line androgen deprivation therapy with LHRH agonist, LHRH antagonist, orchiectomy, high-dose steroid, abiraterone, provenge and ketoconazole.
  3. Patients who have received prior treatment with an mTOR inhibitor.
  4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  5. HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with RAD001.
  6. Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)
  7. Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study.
  8. Prior treatment with any investigational drug within the preceding 4 weeks.
  9. Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent.
  10. Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period.
  11. Patients on herbs or other alternative medicines for the treatment of prostate cancer, including but not limited to saw palmetto, PC-SPES.
  12. Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases.
  13. Other malignancies within the past 3 years except for adequately treated basal or squamous cell carcinomas of the skin or other Stage 0 or I cancers.
  14. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001.
  15. Patients with an active, bleeding diathesis.
  16. History of noncompliance to medical regimens.
  17. Patients unwilling to or unable to comply with the protocol.
  18. Patients with active pulmonary disorders or history of moderately to severely impaired pulmonary function tests will be excluded from the study.
  19. Patients with symptomatic metastatic prostate cancer such as moderate to severe pain, impaired organ function or spinal cord compression will be excluded from this study unless these issues have been taken care of.
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
223646 ( Other Grant/Funding Number: UC Davis )
Novartis ( Other Grant/Funding Number: CRAD001CUS53T )
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
University of California, Davis
University of California, Davis
Principal Investigator: Chong-Xian Pan, MD, PhD University of California, Davis
University of California, Davis
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP